Letter to the Editor: A Phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia

Podobne zapisy

• Fludarabine, cyclophosphamide, and rituximab (FCR) plus GM-CSF as frontline treatment for patients with Chronic Lymphocytic Leukemia
  od: Strati, Paolo, i wsp.
  Wydane: (2013)
• Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
  od: Vitale, Candida, i wsp.
  Wydane: (2019)
• Myelosuppression After Frontline Fludarabine, Cyclophosphamide, and Rituximab in Patients With Chronic Lymphocytic Leukemia: Analysis of Persistent and New-Onset Cytopenia
  od: Strati, Paolo, i wsp.
  Wydane: (2013)
• Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence
  od: Faderl, Stefan, i wsp.
  Wydane: (2010)
• Fludarabine, Cyclophosphamide, and Multiple-Dose Rituximab as Frontline Therapy for Chronic Lymphocytic Leukemia
  od: Short, Nicholas J., i wsp.
  Wydane: (2015)